Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs



Status:Active, not recruiting
Conditions:Hospital
Therapuetic Areas:Other
Healthy:No
Age Range:18 - Any
Updated:4/17/2018
Start Date:May 2011
End Date:December 2020

Use our guide to learn which trials are right for you!

Human donor lungs that do not meet the standard clinical criteria for donor lung utilization
but fit into the study inclusion criteria will be retrieved from the donor using current
donor lung retrieval techniques.

These lungs will be brought to the study transplant center to be re-assessed by the
transplant team. The lungs will be physiologically assessed during ex vivo perfusion with
Steen Solution. Perfusion of these lungs will be performed using Steen solution with the
addition of methylprednisolone, heparin and antibiotics. With respect to the decision of lung
utilization those organs with a delta pO2 (Δ pO2 = Pulmonary vein pO2 - pulmonary artery pO2)
during ex vivo perfusion assessment > 350mmHg, good lung compliance, and a favorable opinion
of the transplant surgeon will be considered transplantable. Lungs will be excluded for
transplantation: if the Δ pO2 is less than 350mmHg or if they demonstrate >10% deterioration
in any of the following functional parameters: pulmonary vascular resistance (PVR), dynamic
compliance or airway pressures. Lungs will also be excluded if they are deemed unsuitable
based on the clinical judgment of the lung transplant surgeon.

Recipient Inclusion/Exclusion Criteria The recipient inclusion/exclusion criteria apply to
patients enrolled in the control or EVLP treatment arms.

1. Recipient Inclusion Criteria

1. Requires single or bilateral lung transplant.

2. Male or Female, 18 years of age or older.

3. Subject or Subject's Representative provides a legally effective informed
consent.

2. Recipient exclusion Criteria

1. A recipient is HIV positive.

2. A recipient has active Hepatitis.

3. Investigator believes that the recipient has infection that excludes them from
transplant in the study.

4. To receive multi-organ transplant.

5. Is on hemodialysis or has chronic severe renal dysfunction. Severe renal
dysfunction is defined as a glomerular filtration rate of 29 or less
(mL/min/1.73m2).

6. Is to have planned concurrent cardiac procedures.

7. A recipient is a re-transplant. (A re-transplant is defined as a recipient having
the removal and transplant of a previously transplanted lung. A recipient with a
previously single lung transplant is eligible to enroll in the trial if it is for
the other lung and within 6 months of previous transplant.)

8. A recipient is on Nova Lung, ECMO, or on mechanical ventilation. (CPAP and BIPAP
are not exclusionary)

Donor Inclusion/Exclusion Criteria for EVLP Assessment

1. Donor Inclusion Criteria

1. The Donor lung must meet the following criteria to proceed with EVLP:

2. At the time of the clinical evaluation , the PaO2/FiO2 ≤ 300mmHg Or If PaO2/FiO2
> 30mmHg and the donor has any one or more of the following donor risk factors:

- Multiple blood transfusions.

- Pulmonary edema detected via CXR, bronchoscopy or palpation of lungs.

- Donation after circulatory death donors.

- Investigator evaluation of donor lung as "unsuitable" for standard criteria
for lung transplant. List reason for "unsuitable" determination.

2. Donor Exclusion Criteria

1. Lung has significant pneumonia and/or persistent purulent secretions on
bronchoscopy as determined by investigator.

2. Donor has known significant aspiration of gastric contents within the lung.

3. Donor lung has significant mechanical lung injury or trauma determined by chest
x-ray, bronchoscopy, CT Scan or visual inspection.

4. Donor lung has active infectious disease such as HIV, Hepatitis B or C, HTLV or
Syphilis. Note: This information is not available at the start of EVLP. Therefore
this criteria can be assessed during or post EVLP, but prior to transplant.

Donor Inclusion/Exclusion Criteria for Transplant Suitability after EVLP

1. Donor Inclusion Criteria for Transplant Suitability

1. Surgeon must be clinically satisfied with the lung evaluation (i.e.) overall
improvement, if not, the reason for refusal must be listed.

2. Stability or improvement of other lung function parameters during EVLP perfusion
- PVR, Compliance, Airway Pressures.

3. Two delta PO2 greater than 350 mmHg, if two delta PO2 mm Hg are not met than
three out of four of the following parameters must be present:

- One delta PO2 of > 350 or absolute PO2 of > 400.

- Chest x-ray findings with absence or improvement of pulmonary
edema/infiltrates

- Compliance static (greater than 35 single and greater than 60 for a double)

- Absence of consolidation by palpation

2. Donor Exclusion Criteria for Transplant Suitability after EVLP

1. All delta PO2 (s) are less than 350 mmHg (measured with a FiO2 set at 1.0) or all
absolute PO2s are less than 400.

2. Overall greater than 10-15% Functional deterioration of other lung function
across all parameters (PVR, Compliance, PawP) with chest x-ray findings showing
deterioration.

3. Donor lung positive for infectious diseases such as HIV, Hepatitis B or C, or
Syphilis.

Note: This information is not available until at the start of EVLP. Therefore this criteria
can be assessed during or post EVLP, but prior to transplant.
We found this trial at
18
sites
1959 NE Pacific St
Seattle, Washington 98195
(206) 598-3300
Principal Investigator: Michael Mulligan, MD
Phone: 206-224-3341
University of Washington Medical Center University of Washington Medical Center is one of the nation's...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
75 Francis street
Boston, Massachusetts 02115
(617) 732-5500
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
?
mi
from
Boston, MA
Click here to add this to my saved trials
5801 South Ellis Avenue
Chicago, Illinois 60637
 773.702.1234
Principal Investigator: Christopher Wigfield, MD
Phone: 773-834-9024
University of Chicago One of the world's premier academic and research institutions, the University of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Durham, North Carolina 27710
(919) 684-8111
Principal Investigator: Mani Daneshmand, MD
Phone: 919-681-5925
Duke University Younger than most other prestigious U.S. research universities, Duke University consistently ranks among...
?
mi
from
Durham, NC
Click here to add this to my saved trials
Gainesville, Florida 32611
(352) 392-3261
Principal Investigator: Tiago Machuca, MD
Phone: 352-273-7837
University of Florida Gainesville UF has a long history of established programs in international education,...
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
8700 Beverly Blvd # 8211
Los Angeles, California 90048
(1-800-233-2771)
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
4200 Fifth Ave
Pittsburgh, Pennsylvania 15260
(412) 624-4141
Principal Investigator: Jonathan D'Cunha, MD
Phone: 412-647-8323
University of Pittsburgh The University of Pittsburgh is a state-related research university, founded as the...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
1 Tampa General Cir
Tampa, Florida 33606
(813) 844-7000
Principal Investigator: Christiano Calderia, MD
Phone: 813-844-3430
Tampa General Hospital In a diverse city known for its rich culture and beautiful beaches,...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
500 S State St
Ann Arbor, Michigan 48109
(734) 764-1817
Principal Investigator: William Lynch, MD
Phone: 734-615-8627
University of Michigan The University of Michigan was founded in 1817 as one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Aurora, Colorado 80045
Principal Investigator: Michael Weyant, MD
Phone: 303-724-2800
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Baltimore, Maryland 20742
(301) 405-1000
University of Maryland As a globally-connected university offering a world-class education, the University of Maryland...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
281 W. Lane Ave
Columbus, Ohio 43210
(614) 292-6446
Principal Investigator: Bryan Whitson, MD, PhD
Phone: 614-685-5695
Ohio State University The Ohio State University’s main Columbus campus is one of America’s largest...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Dallas, Texas 75390
Principal Investigator: Michael Jessen, MD
Phone: 214-645-7721
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Detroit, Michigan 48202
Principal Investigator: Hassan Nemeh, MD
Phone: 313-916-1011
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Indianapolis, Indiana 46202
Principal Investigator: Thomas Wozniak, MD
Phone: 317-962-9904
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
New York, New York 10032
Principal Investigator: Frank D'Ovidio, MD
Phone: 212-342-5226
?
mi
from
New York, NY
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Principal Investigator: Edward Cantu, MD
Phone: 215-615-6582
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Saint Louis, Missouri 63110
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials